Low-dose 'natural' alpha-interferon in B-cell derived chronic lymphocytic leukemia

G. Pozzato; F. Franzin; M. Moretti; P. Tulissi; P. Pecorari; M. Melato; T. Zacchi; P. Evangelisti; L. Campanacci

Low-dose 'natural' alpha-interferon in B-cell derived chronic lymphocytic leukemia

G. Pozzato, F. Franzin, M. Moretti, P. Tulissi, P. Pecorari, M. Melato, T. Zacchi, P. Evangelisti, L. Campanacci

IRCCS pediatrico Burlo Garofolo

Research output: Contribution to journal › Article › peer-review

Abstract

Background. Alpha-interferon (alpha-IFN) was found to have a good antiproliferative effect in early stage chronic lymphocytic leukemia (CLL), but recombinant alpha-IFN administration may induce serious side effects. Therefore low-dose 'natural' IFN was evaluated in terms of efficacy and safety. Methods. Fifteen patients affected by stage A (according to Binet) B-CLL underwent the treatment: natural IFN 1 MU three times a week for 6 months. Results. Overall lymphocyte count decreased from 13.050 ± 3.200 to 7.500 ± 2.940 within 6 months. One patient did not respond to IFN therapy. No one complained of side effects. Conclusion: Low dose 'natural' alpha-IFN seems useful and well tolerated in CLL, but the potential curative role of IFN in CLL remains to be established.

Original language	English
Pages (from-to)	413-417
Number of pages	5
Journal	Haematologica
Volume	77
Issue number	5
Publication status	Published - 1992

ASJC Scopus subject areas

Hematology

Fingerprint Dive into the research topics of 'Low-dose 'natural' alpha-interferon in B-cell derived chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this

@article{16499e72e05442e4ab1ed635c058b4f7,

title = "Low-dose 'natural' alpha-interferon in B-cell derived chronic lymphocytic leukemia",

abstract = "Background. Alpha-interferon (alpha-IFN) was found to have a good antiproliferative effect in early stage chronic lymphocytic leukemia (CLL), but recombinant alpha-IFN administration may induce serious side effects. Therefore low-dose 'natural' IFN was evaluated in terms of efficacy and safety. Methods. Fifteen patients affected by stage A (according to Binet) B-CLL underwent the treatment: natural IFN 1 MU three times a week for 6 months. Results. Overall lymphocyte count decreased from 13.050 ± 3.200 to 7.500 ± 2.940 within 6 months. One patient did not respond to IFN therapy. No one complained of side effects. Conclusion: Low dose 'natural' alpha-IFN seems useful and well tolerated in CLL, but the potential curative role of IFN in CLL remains to be established.",

author = "G. Pozzato and F. Franzin and M. Moretti and P. Tulissi and P. Pecorari and M. Melato and T. Zacchi and P. Evangelisti and L. Campanacci",

year = "1992",

language = "English",

volume = "77",

pages = "413--417",

journal = "Haematologica",

issn = "0390-6078",

publisher = "NLM (Medline)",

number = "5",

}

TY - JOUR

T1 - Low-dose 'natural' alpha-interferon in B-cell derived chronic lymphocytic leukemia

AU - Pozzato, G.

AU - Franzin, F.

AU - Moretti, M.

AU - Tulissi, P.

AU - Pecorari, P.

AU - Melato, M.

AU - Zacchi, T.

AU - Evangelisti, P.

AU - Campanacci, L.

PY - 1992

Y1 - 1992

N2 - Background. Alpha-interferon (alpha-IFN) was found to have a good antiproliferative effect in early stage chronic lymphocytic leukemia (CLL), but recombinant alpha-IFN administration may induce serious side effects. Therefore low-dose 'natural' IFN was evaluated in terms of efficacy and safety. Methods. Fifteen patients affected by stage A (according to Binet) B-CLL underwent the treatment: natural IFN 1 MU three times a week for 6 months. Results. Overall lymphocyte count decreased from 13.050 ± 3.200 to 7.500 ± 2.940 within 6 months. One patient did not respond to IFN therapy. No one complained of side effects. Conclusion: Low dose 'natural' alpha-IFN seems useful and well tolerated in CLL, but the potential curative role of IFN in CLL remains to be established.

AB - Background. Alpha-interferon (alpha-IFN) was found to have a good antiproliferative effect in early stage chronic lymphocytic leukemia (CLL), but recombinant alpha-IFN administration may induce serious side effects. Therefore low-dose 'natural' IFN was evaluated in terms of efficacy and safety. Methods. Fifteen patients affected by stage A (according to Binet) B-CLL underwent the treatment: natural IFN 1 MU three times a week for 6 months. Results. Overall lymphocyte count decreased from 13.050 ± 3.200 to 7.500 ± 2.940 within 6 months. One patient did not respond to IFN therapy. No one complained of side effects. Conclusion: Low dose 'natural' alpha-IFN seems useful and well tolerated in CLL, but the potential curative role of IFN in CLL remains to be established.

UR - http://www.scopus.com/inward/record.url?scp=0026620663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026620663&partnerID=8YFLogxK

M3 - Article

C2 - 1483591

AN - SCOPUS:0026620663

VL - 77

SP - 413

EP - 417

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -